Drug

Telmisartan

Approved · EMA

Late-stage development

Also known as 4'-((4-methyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimidazolyl)methyl)-2-biphenylcarboxylic acid, Micardis, Micardis HCT, Micardis-HCT+5 more

4'-((4-methyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimidazolyl)methyl)-2-biphenylcarboxylic acid, Micardis, Micardis HCT, Micardis-HCT, Semintra, Twynsta, Widaplik, Hydrochlorothiazide-Telmisartan, 4'-((1,4'-dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)-(1,1'-biphenyl)-2-carboxylic acid.

RxNorm73494 ChEMBLCHEMBL1017UNIIU5SYW473RQ

Active clinical trials

Regulatory events

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Pilot Randomized Clinical Trial to Assess Feasibility, Safety, and Efficacy of Rapid, Simultaneous Therapy Initiation in Chronic Kidney Disease and Type 2 Diabetes: RAPID-CKD

Clinical trial2026-05-08Results expected Q1 2029 · ClinicalTrials.gov

Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes: A Hybrid Design in a Real-World Setting

Clinical trial2026-05-06Results expected Q2 2028 · ClinicalTrials.gov

Study of Antihypertensive Treatment and Cardiovascular Risk in Chinese Prehypertensive Population

Clinical trial2026-04-30Completed · ClinicalTrials.gov

Phase I Non-Randomized, Unblinded, Single-Center Trial of Oral Telmisartan Alone or Combined With Selected Standard of Care Therapies for Prostate Cancer

Clinical trial2026-04-01Primary completion · ClinicalTrials.gov

Efficacy of Telmisartan in Preventing Doxorubicin-induced Cardiotoxicity in Breast Cancer Patients

Clinical trial2026-01-29Results expected Q1 2027 · ClinicalTrials.gov

Phase II Non-Randomized, Unblinded, Single-Center Trial of Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer Versus Historical Best Supportive Care

Clinical trial2026-01-28Results expected Q2 2027 · ClinicalTrials.gov

A Multi-center, Randomized, Open-label, Active Comparator-controlled, Phase 4 Clinical Trial To Evaluate the Efficacy and Safety of Telmisartan Compared With Losartan in Patients With Diabetic Nephropathy and Hypertension

Clinical trial2025-10-31Primary completion · ClinicalTrials.gov

Edmond J Safra, Accelerating Clinical Trials in Parkinson's Disease (EJS ACT-PD) - a Multi-arm Multi-stage Platform Trial for Potential Disease Modifying Approaches.

Clinical trial2025-10-03Results expected Q2 2031 · ClinicalTrials.gov

Approval: Telmisartan Actavis (EMA)

Regulatory2010-09-29EMA

Approval: Tolura (EMA)

Regulatory2010-06-04EMA

Approval: Kinzalmono (previously Telmisartan Boehringer Ingelheim Pharma KG) (EMA)

Regulatory1998-12-16EMA

Approval: Micardis (EMA)

Regulatory1998-12-16EMA

Evidence confidence

1 claim

How strongly the incorporated evidence supports specific clinical claims about this treatment. A confidence figure is a current summary of evidence strength, not a permanent verdict.

Lowers systolic blood pressure in hypertension

47%Low confidence

Uncertainty ±23%Evidence coverage: HighUpdated 30 April 2026

High point estimate, but substantial uncertainty remains.

Evidence is mixed — 4 supporting evidence families · contradictory evidence

Confidence has a low point estimate but a wide uncertainty band — the evidence base is still thin.

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Telmisartan

Aliases & brands

4'-((4-methyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimidazolyl)methyl)-2-biphenylcarboxylic acidMicardisMicardis HCTMicardis-HCTSemintraTwynstaWidaplikHydrochlorothiazide-Telmisartan4'-((1,4'-dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)-(1,1'-biphenyl)-2-carboxylic acid

RxNorm CUI

73494

ChEMBL ID

CHEMBL1017

UNII

U5SYW473RQ

Regulatory jurisdictions

ema

Regulatory timeline

5 events

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval

1998-12-11

Latest approval

2010-09-29

Authorities

EMA

Total events

emaEuropean Medicines Agency· 5 events

2010-09-29Approval

Approval: Telmisartan Actavis (EMA)

Indication: Hypertension Treatment of essential hypertension in adults. Cardiovascular prevention Reduction of cardiovascular morbidity in patients with: manifest atherothrombotic… Show full indication

Hypertension Treatment of essential hypertension in adults. Cardiovascular prevention Reduction of cardiovascular morbidity in patients with: manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or; type 2 diabetes mellitus with documented target organ damage.

Evidence ↗

2010-06-04Approval

Approval: Tolura (EMA)

Hypertension Treatment of essential hypertension in adults. Cardiovascular prevention Reduction of cardiovascular morbidity in patients with: manifest atherothrombotic cardiovascular disease (history of coronary heart disease or peripheral arterial disease) or; type 2 diabetes mellitus with documented target organ damage.

Evidence ↗

1998-12-16Approval

Approval: Micardis (EMA)

Hypertension Treatment of essential hypertension in adults. Cardiovascular prevention Reduction of cardiovascular morbidity in patients with: manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or; type-2 diabetes mellitus with documented target-organ damage.

Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.